Um, and, and so why is nem leukin important? Um, and why is this different from, from IL2? Well, Neleukin, you know, what is it first of all, right? This is a fusion protein, IL2, uh, with, uh, an IL2 alpha receptor fragment basically. And what that does is it hysterically inhibits the binding um of nevolleukin to uh the heterotrimeric IL2 receptor, right, the alpha beta gamma. And so why is that all important? And when we think about the activity of IL to, um, simplistically, right, we can think of it as having two arms. One, the effector arm where we get that, um, um, um, you know, T cell engagement, activation of NK cells, activation of um the kind activator killer cells, right? Um, all of those, um, um. Or is that that's the activity we want to do. On the flip side, IL2 also activates um. The uh immunosuppressive arms, regulatory cells, and so forth. Those T regulatory cells um are most activated by the heterotrimeric IL2 receptors, so alpha, beta gamma. Um, whereas that T cell, um, response, um, is more activated by the beta gamma response. And so with Nemvolleukin, the way it was engineered, um, it's engineered to more strongly bind to this intermediate affinity, effector arm of the IL2 activity and not activate the T regulatory cells. And so That in a large part I think is leading to uh the increased efficacy that we're seeing, the broader efficacy that we're seeing across um cancers where we didn't see it before. Right? Like platinum versus an ovarian cancer, um, that's not something that we typically thought as an as an IL2 responsive tumor, but now we're seeing a promising activity with numba leukin. In addition, the toxicity profile is certainly uh um much, much better with nevolleukin. Uh, we don't see the capillary league syndrome. Uh, we're able to manage this as an outpatient. We do see things like neutropenia certainly, um, uh, but that's, that's manageable. Um, and so I think, again, the ability to more rationally engineer these cytokines, uh, to preferentially activate the affective arm of the immune system and not activate the immunosuppressive piece, uh, I think is really, really exciting.
Presenter
